Announced Fri, 14 Aug · 16:54 IST
Rubicon Research Q1 FY27: Revenue up 54%, PAT up 135% YoY
Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionResults View source PDFExplain this filing
RUBICON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+12.5%1-day move
₹1611.80
prior close
₹1700.70
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-1.5-3.7-2.8-2.7+12.5+11.1+9.2+7.1——————
Up moveDown movePending
AI summary
Rubicon Research Q1 FY27: Standalone revenue at ₹4,277.30M (up 53.8% YoY), net profit at ₹824.49M (up 134.6%). Consolidated revenue at ₹5,343.38M (up 51.6%), PAT at ₹847.81M (up 95.8%). Growth aided by 85% stake acquisition in Arinna Lifesciences completed April 30, 2026. Board approved amalgamation of Kia Health Tech. Clean limited review by Deloitte Haskins & Sells. ₹805.69M IPO proceeds still unutilised, deadline extended to March 31, 2027.
Likely market impact
Strong double-digit growth in revenue and profit, aided by acquisition. Clean audit. Positive for shareholders; watch IPO funds deployment.